Trastuzumab Deruxtecan for HER2-mutant lung cancer before surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that has spread to nearby lymph nodes but not to distant parts of the body.
- Your tumor must have a specific change in the HER2 gene, found through a blood or tissue test.
- You must be healthy enough for lung surgery, with good lung and heart function.
- You cannot have had any prior treatment for lung cancer within the last 3 years.
- You must not have a history of lung inflammation (interstitial lung disease) or other serious lung conditions.
- You must agree to use effective birth control during and for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
This trial tests a drug called trastuzumab deruxtecan (an antibody-drug conjugate) in people with advanced non-small cell lung cancer that has high levels of HER2. The drug is designed to target and kill cancer cells while sparing healthy cells, and the study will see how well it works and how safe it is.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests a combination of two drugs (trastuzumab deruxtecan and an immunotherapy) given before surgery to shrink early-stage breast cancer tumors. It is for people whose tumors have low levels of HER2 and are hormone receptor positive.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.